Skip to content
MarketScale
Demo
Creator Hubs›Carevive

Carevive

Carevive logo

Remote oncology monitoring that connects clinicians and cancer patients between visits.

Carevive is an oncology health technology company that gives care teams a remote patient monitoring platform to track symptoms, collect patient-reported outcomes, and manage cancer patients between clinic visits. The system is designed to surface actionable data for clinicians while reducing the burden on patients managing complex treatment regimens. On MarketScale, Carevive publishes content for oncology administrators, clinicians, and health systems evaluating remote care management tools.

51 episodes
Channel Brief·Carevive · 51 episodes
Updated Jan 9, 2023

Patient data drives oncology payment model transition and real-world insights

Carevive argues that continuous, patient-reported outcome data collected at point of care reshapes how oncology centers operate under new payment models and informs clinical decision-making with real-world evidence.

Carevive's core argument is that oncology care improves when patient-reported outcomes (PROs) are captured in real time during active treatment and fed directly back to care teams for immediate action. The channel documents this through webinars and case studies showing how continuous symptom monitoring, alert triggers for moderate-to-severe symptoms, and longitudinal data collection create what Carevive calls smart data, enabling both treatment adjustments and understanding of the full patient experience beyond clinical trial populations.

Drawn from Carevive’s Longitudinal Data and 3 more →

“Integrating patient-reported outcomes into the workflow leads to improved patient adherence to therapy and reduced hospitalizations and emergency room visits.”

Episode 23: CV/COS Webinar: Clip 11

By the numbers

600,000

unique data points from over 1,700 patients across 26 cancer types

19,000

completed surveys from Carevive registry over two years

26

cancer types represented in Carevive longitudinal dataset

July 1, 2023

EOM replaces OCM for oncology payment and care models

What the channel argues

DataCarevive's platform captures over 600,000 unique data points from 1,700+ patients across 26 cancer types.→
InsightThe Oncology Care Model (OCM) is being phased out July 1, 2023, and replaced with the Enhanced Oncology Model (EOM).→
InsightReal-time PRO data integration into clinical workflows enables alert-triggered interventions for moderate-to-severe symptoms.→
DataCarevive's registry contains over 19,000 completed surveys conducted over two years across its patient population.→
InsightReal-world data platforms capture patient populations beyond the healthiest trial-eligible cohorts, offering broader treatment outcome insights.→

What you'll learn

•The Enhanced Oncology Model replaces OCM on July 1, 2023, and focuses on seven common cancer types with emphasis on health equity and accountable care.
•Carevive's platform integrates patient symptom reporting directly into clinical workflows, triggering care team alerts for moderate-to-severe symptoms in real time.
•Longitudinal patient data collected during active treatment phases reveals both treatment tolerability patterns and key patient concerns like cost of care and treatment decision confidence.
•Real-world data from standard-of-care populations provides FDA-relevant PRO measure insights for clinical trial planning that remain current as oncology standards evolve.
•Patient survey compliance during the critical first three months of treatment is high, enabling continuous monitoring of treatment adherence and early intervention opportunities.

What to do about it

→Audit your current patient-reported outcome collection process against Carevive's end-to-end technology model to identify integration gaps between questionnaire delivery and care team workflow.
→Assess how your oncology center will transition operational and revenue strategies from OCM to EOM by July 2023, including data infrastructure and alert response protocols.
→Establish alert-response protocols for moderate-to-severe patient-reported symptoms to capture the documented benefits of improved adherence and reduced hospitalizations and ER visits.

Who and what shows up

Dr. Aaron Galaznik

Chief Scientific Officer, Carevive

Led NSCLC webinar on smart data insights and featured in discussions on alert systems, PRO platform capabilities, and longitudinal analysis across cancer types.

John Elliot

Vice President of Sales, Carevive

Interviewed on OCM-to-EOM transition and revenue-enhancing opportunities in the new model for oncology centers.

Dr. Ethan Basch

Healthcare expert

Led webinar on digital remote monitoring and electronic patient-reported outcomes implementation, troubleshooting ePRO data collection and provider engagement.

Tyler Kern

Host, Oncology and Technology podcast

Interviewed Carevive team members on the Enhanced Oncology Model implementation and expectations for cancer care improvements.

Michelle Dawn Mooney

Host, Technology and Oncology Podcast

Conducted interview with John Elliot on revenue-enhancing opportunities and benefits of transitioning from OCM to EOM.

Questions this channel answers

Q

What is the difference between the Oncology Care Model (OCM) and the Enhanced Oncology Model (EOM)?

OCM, launched in 2016, transitions oncology centers from fee-for-service to high-value care. EOM replaces OCM on July 1, 2023, supporting clinicians caring for seven common cancer types with focus on health equity and accountable, affordable care.

Revenue Enhancing Opportunities: The Switch from OCM to … →
Q

How does Carevive's platform differ from traditional big data approaches in oncology?

Traditional big data provides discrete, sequential snapshots of patient health status. Carevive's platform captures continuous, patient-reported outcome data directly from patients at point of care, enabling ongoing assessment of treatment experience rather than periodic snapshots.

Improving the Patient Experience in Cancer →
Q

What evidence shows that integrating PROs into clinical workflows improves patient outcomes?

Studies including Carevive's own data demonstrate that integrating PROs into workflow leads to improved patient adherence to therapy and reduced hospitalizations and emergency room visits.

CV/COS Webinar: Clip 11 →
Q

How does Carevive use real-world data to support clinical trial design?

Carevive's real-time data from standard-of-care populations offers contemporary FDA-relevant insights for PRO measure selection in clinical trials, staying current as oncology standards rapidly evolve, unlike historical trial data.

CV/COS Webinar: Applications and Future Directions →
Q

What are the key patient concerns identified in lung cancer populations?

Patient concerns in non-small cell lung cancer cohorts center on cost of care and making the right treatment decisions, reflecting the complexities of multiple treatment options available.

Patient Insights – Concerns and Symptom Experience over … →
Topics:Patient-reported outcomes (PROs) in oncologyEnhanced Oncology Model (EOM) payment transitionReal-world longitudinal data collectionSymptom monitoring and alert systemsClinical trial design and post-marketing research
Themes:Patient voice as clinical infrastructureReal-world evidence beyond trial populationsActionable data at point of care

Industry context

The global oncology market is projected to grow at 11.31% CAGR through 2035, driven by advances in treatment modalities and expanded clinical research infrastructure for cancer care delivery.

Want a show like this for your brand?

MarketScale produces and distributes branded shows like Carevive for B2B companies.

Build your show →